<DOC>
	<DOCNO>NCT01077921</DOCNO>
	<brief_summary>An open label , prospective , randomized cross-over phase II study 60 sickle cell patient either homozygous Hb S HbSB0 thalassemia . Initially , patient treat 6 week placebo standard dose propranolol ( 40 mg ) every 12 hr . This follow 2-week washout period , patient receive treatment modality ( placebo propranolol ) . We Hypothesize propranolol administer vivo daily basis 6 week ( 1 ) decrease baseline adhesion endothelial cell substantially abrogate epinephrine-stimulated adhesion endothelial cell , measure vitro ; ( 2 ) improve biomarkers endothelial activation dysfunction ; ( 3 ) safely used patient SCD . Thus , use propranolol SCD may represent safe effective mean anti-adhesive therapy SCD . Study Objectives : Primary Objective : • To establish safety efficacy long-term therapy propranolol anti-adhesive therapy SCD . Secondary Objective : • To evaluate change soluble marker endothelial activation dysfunction . Correlative Science Objective : • To determine whether response propranolol therapy associate polymorphisms gene encode protein involve upregulation Sickle Red Blood Cell ( SS RBC ) adhesion epinephrine .</brief_summary>
	<brief_title>Study Propranolol Anti-Adhesive Therapy Sickle Cell Disease ( SCD )</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Diagnosis electrophoresis ( HEP ) Hemoglobin ( Hgb ) SS Hgb Sβ0 thalassemia ( patient follow clinic HEPconfirmed diagnosis file ) Age ≥ 18 year Blood pressure ( BP ) Systolic ≥ 95mm Hg Diastolic ≥ 50mm Hg Heart rate ( HR ) ≥ 70 ≤ 110 bpm Oxygen saturation pulse oximeter room air ≥ 92 % Hematocrit ( Hct ) ≥ 20 % Hb &gt; 6.0 g/dL Euthyroid status indicate normal Thyroid Stimulating Hormone ( TSH ) SS RBCs obtain screen period demonstrate adhesion response epinephrine 40 % nonstimulated baseline adhesion endothelial cell Capacity understand sign inform consent History vasoocclusive episode 6 wks prior screen RBC transfusion 3 month prior study entry Ongoing pregnancy History heart failure , myocardial infarct ( MI ) , bradyarrhythmias , conduction defect History asthma reactive airway disease History thyroid disease Diabetes Renal insufficiency ( BUN &gt; 21 mg/dL and/or Creatinine &gt; 1.4 mg/dL ) Use screen study period follow medication : antihypertensive , diuretic , thyroid replacement therapy , antiarrhythmia medication , bronchodilator , inhaled steroid , insulin , hypoglycemic medication History allergy sulfonamide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>sickle</keyword>
	<keyword>adhesion</keyword>
	<keyword>propranolol</keyword>
</DOC>